Molecular analyses showed that compound 3 affected downstream Hippo signaling components (YAP, TAZ, pan-TEAD) in liver cancer cells and inhibited pro-survival pathways-including phosphorylated AKT-in lung cancer cells, where it also elevated apoptotic markers Bax and cleaved caspase-3 while reducing anti-apoptotic BCL-2. This evidence concerns the gene CASP3 and lung carcinoma.